We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Merck & Co., Inc.
Health Care · Pharmaceuticals
Structural read: $MRK is a single-asset story trading on Keytruda concentration risk vs. pipeline-replacement credibility into the 2028 LOE. Keytruda is ~45-50% of pharma revenue at a >$25B/yr run-rate, and the subcutaneous reformulation (Keytruda Qlex) is the primary lifecycle-extension lever - early uptake and payer coverage are the gating variables for how much revenue carries past the IV biosimilar cliff.
Animal Health and Vaccines (Gardasil, Pneumovax) provide a $15B+ non-oncology base. The bull/bear gap is wide because the post-2028 pipeline (Winrevair PAH, oral PCSK9, ADC platform via Daiichi Sankyo collab, cardiometabolic) has to compound through M&A and clinical readouts to fill the hole.
- Keytruda subcutaneous launches 2025-2026; if payer mix converts >50%, a material share of $25B+ franchise extends past 2028 IV LOE
- Winrevair (acquired via Acceleron) ramping in PAH, consensus modeling $5B+ peak
- Daiichi Sankyo ADC collaboration (patritumab, ifinatamab, raludotatug) adds 3 late-stage oncology shots on goal
- Animal Health + Vaccines provide >$15B durable non-oncology revenue base, low LOE exposure
- Keytruda US LOE 2028, EU 2030 - biosimilars compress 50-70% of franchise value within 24 months absent SC conversion
- Gardasil China inventory destocking persistent through 2025-2026, key growth engine stalled
- Pipeline depth below Keytruda is thin vs $LLY, $NVO, $JNJ; M&A premium required to fill the gap
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
- China policy + IRA Medicare negotiation cycle adds 2027-2030 pricing headwind on top of LOE